- Dynavax (NASDAQ:DVAX) gained 9.3% after its announcement that an amendment to its collaboration deal with AstraZeneca (AZN -0.1%) means that AstraZeneca, not Dynavax, will conduct a Phase 2a trial of AZD1419 in asthma patients.
- The safety and efficacy trial will take place this year. A previous Phase 1a study showed ascending doses of AZD1419 were well tolerated in patients.
- The treatment is a second-generation TLR9 agonist CpG oligodeoxynucleotide formulated for inhalation use.
- After hours today: AZN -0.8%.